Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02744053 · ClinicalTrials.gov registry record · Early Phase 1
DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer
A Early Phase 1 study of HER2/Neu Negative and Triple-Negative Breast Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Early Phase 1
- Development phase
- 96
- Enrollment target
- 6
- Study locations
NCT02744053 is a Early Phase 1 study of HER2/Neu Negative and Triple-Negative Breast Carcinoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 96 participants, below the 164-participant average among 28 other HER2/Neu Negative trials with a reported enrollment target (41% lower). The trial reports 6 study locations across 1 state.
The verdict
NCT02744053, a Early Phase 1 study of HER2/Neu Negative and Triple-Negative Breast Carcinoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 96 participants
- Enrollment target
- 6
- Study locations
Study Summary
This early phase I trial studies how well dynamic contrast enhanced molecular resonance imaging (DCE-MRI) and technetium-Tc99m sestamibi molecular breast imaging (MBI) work in assessing tumor response to chemotherapy in patients with triple negative breast cancer (TNBC) who are undergoing chemotherapy. Investigational imaging scans such as MBI and DCE-MRI may help researchers predict which patients may respond to treatment.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- RADIATION Scintimammography
- PROCEDURE Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- DRUG Technetium Tc-99m Sestamibi
Study Locations (6)
Texas
- Memorial Hermann Memorial City Medical Center - Houston
- M D Anderson Cancer Center - Houston
- MD Anderson in Katy - Houston
- MD Anderson League City - Nassau Bay
- MD Anderson in Sugar Land - Sugar Land
- MD Anderson in The Woodlands - The Woodlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2016-11-07 |
| Est. Completion | 2026-04-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02744053
The ClinicalTrials.gov registry entry for NCT02744053 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 164-participant average among 28 other HER2/Neu Negative trials with a reported enrollment target (41% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with HER2/Neu Negative appearing as the primary indexed condition, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02744053 reports 6 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02744053 about?
NCT02744053 is a clinical study titled "DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer". This early phase I trial studies how well dynamic contrast enhanced molecular resonance imaging (DCE-MRI) and technetium-Tc99m sestamibi molecular breast imaging (MBI) work in assessing tumor response to chemotherapy in patients with triple negative breast cancer (TNBC) who are undergoing chemothera...
What is the current status of trial NCT02744053?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 96 participants. The study started on 2016-11-07. Estimated completion is 2026-04-30.
What conditions does trial NCT02744053 study?
This clinical trial studies the following conditions: HER2/Neu Negative, Triple-Negative Breast Carcinoma, Estrogen Receptor Negative, Progesterone Receptor Negative.
What interventions are being tested in trial NCT02744053?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Scintimammography (RADIATION), Dynamic Contrast-Enhanced Magnetic Resonance Imaging (PROCEDURE), Technetium Tc-99m Sestamibi (DRUG).
Who is sponsoring clinical trial NCT02744053?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02744053 being conducted?
This trial has 6 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2/Neu Negative
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
RECRUITING · NA
-
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
RECRUITING · Phase 2
-
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
RECRUITING · NA
-
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
RECRUITING · Phase 2
-
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
ACTIVE NOT RECRUITING · Phase 3
-
Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.